Cancer Cytogenetics: Chromosomal And Molecular Genetic Aberrations Of Tumor Cells, Fourth Edition

Over the last four decades, cancer cytogenetics has become widely recognized as both a basic research tool for investigations of tumor biology and a clinical methodology providing vital insights into cancer development and progression. The first three editions of this acclaimed book presented a much-needed conceptual synthesis of this rapidly moving field. Now, Cancer Cytogenetics, Fourth Edition, offers a comprehensive, expanded, and up-to-date review of recent dramatic advances in this area, incorporating a vast amount of new data from the latest basic and clinical investigations.

Edited by two leading experts, and now involving an expanded panel of international experts, the book offers an authoritative description of neoplastic processes at the chromosomal level of genomic organization. Now in full color, Cancer Cytogenetics, Fourth Edition, features the following:

Includes a complete coverage of chromosome aberrations in cancer based on an assessment of the 60 000 neoplasms cytogenetically investigated to date

Offers greater emphasis throughout on the clinical importance and application of information about cytogenetic and molecular aberrations

Covers how molecular genetic data (PCR-based and sequencing information) are collated with the cytogenetic data where pertinent

Discusses how molecular cytogenetic data (based on studies using FISH, CGH, SNP, etc.) are fused with karyotyping data to enable an as comprehensive understanding of cancer cytogenetics as is currently possible.

Cancer researchers, clinical oncologists, geneticists, and especially anyone interested in the translational aspects of bench-to-bedside research in cancer genetics will find this new edition indispensable as a reference and clinical tool.

Sverre Heim has worked within the field of cancer cytogenetics for more than three decades. He has used chromosomal markers to trace the clonal relationships among neoplastic cell populations and determine their patterns of evolution. He has described numerous specific chromosome abnormalities in various hematologic disorders and solid tumors, has identified their gene-level consequences, and has shown that the karyotypic and molecular genetic abnormalities have diagnostic as well as prognostic consequences. Dr Heim has served as a member of several editorial boards and scientific advisory committees. He is the author of nearly 500 scientific publications.

Felix Mitelman has published more than 750 articles in the field of cancer cytogenetics. In the early 1980s, he established a unique database on chromosome changes in cancer-a systematic compilation of reported acquired cytogenetic aberrations, the molecular genetic outcome of the cytogenetic abnormalities, and the clinical consequences of the genetic changes. In 1989, Dr Mitelman founded the journal Genes, Chromosomes & Cancer and he has since served as the Editor-in-Chief. He is an elected member of several distinguished societies, including the Royal Swedish Academy of Sciences and the American Academy of Arts and Sciences.

Professor Sverre Heim has worked within the field of cancer cytogenetics for more than three decades. He has used chromosomal markers to trace the clonal relationships among neoplastic cell populations and determine their patterns of evolution. He has described numerous specific chromosome abnormalities in various hematologic disorders and solid tumors, identified their gene-level consequences, and has shown that the karyotypic and molecular genetic abnormalities have diagnostic as well as prognostic consequences. Dr Heim has served as a member of several editorial boards and scientific advisory committees. He is the author of nearly 500 scientific publications.

Professor Felix Mitelman has published more than 750 articles in the field of cancer cytogenetics. In the early 1980s, he established a unique database on chromosome changes in cancer – a systematic compilation of reported acquired cytogenetic aberrations, the molecular genetic outcome of the cytogenetic abnormalities, and the clinical consequences of the genetic changes. In 1989, Dr Mitelman founded the journalGenes, Chromosomes & Cancer and he has since served as the Editor-in-Chief. He is an elected member of several distinguished societies, including the Royal Swedish Academy of Sciences and the American Academy of Arts and Sciences.